+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cell & Gene Therapy Drug Delivery Devices Market by Products, Commercialized Drugs - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011242
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cell & Gene Therapy Drug Delivery Devices Market grew from USD 1.08 billion in 2023 to USD 1.17 billion in 2024. It is expected to continue growing at a CAGR of 9.78%, reaching USD 2.08 billion by 2030.

The scope of the cell and gene therapy drug delivery devices market encompasses various devices specifically designed for the efficient delivery of therapeutic genes or cells to targeted sites within the body. This market's necessity arises from the growing demand for precise and effective treatments for complex conditions like cancer, genetic disorders, and chronic diseases. These devices serve applications in clinical settings for both research and treatment purposes, with end-use scope including hospitals, research institutes, and biopharmaceutical companies. Key factors driving growth in this market include technological advancements in drug delivery systems, increasing adoption of personalized medicine, and the rising prevalence of chronic diseases worldwide. Additionally, significant investments in biopharmaceutical R&D and favorable regulatory environments foster growth.

Potential opportunities lie in advancements in nanotechnology for more targeted delivery and in the development of non-viral vectors that promise to address safety concerns associated with viral vectors. Companies should focus on collaborations and partnerships to leverage technologies and expand applications, particularly in unmet therapeutic areas. However, market growth is constrained by high costs associated with these therapies, complex manufacturing processes, and stringent regulatory challenges. Competition from alternative therapies and ethical concerns related to genetic modifications also present challenges.

For business growth, areas ripe for innovation include the development of next-generation vectors with improved safety and efficacy profiles, smart delivery systems using AI for predictive analytics in patient response, and novel materials for biodegradable delivery devices. The market is dynamic, shaped by rapid technological advances and regulatory developments. Companies should stay updated with regulatory guidelines and actively engage in clinical trials to establish efficacy and safety profiles. Expanding into emerging markets through strategic collaborations could also provide a competitive edge. The overall nature of the market is highly niche yet expansive with potential for significant impact on global healthcare outcomes through personalized, targeted therapies.

Understanding Market Dynamics in the Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising number of chronic and genetic disorders
    • Growing number of drug approvals for treatment of cellular and genetic disorders
    • Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
  • Market Restraints
    • High cost of drug delivery devices
  • Market Opportunities
    • Advancements in nanotechnology and development of biomaterials
    • Utilization of AI, ML, and sensor technologies for drug delivery
  • Market Challenges
    • Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices

Exploring Porter’s Five Forces for the Cell & Gene Therapy Drug Delivery Devices Market

Porter’s Five Forces framework further strengthens the insights of the Cell & Gene Therapy Drug Delivery Devices Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cell & Gene Therapy Drug Delivery Devices Market

External macro-environmental factors deeply influence the performance of the Cell & Gene Therapy Drug Delivery Devices Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Drug Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC, Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd., Kite Pharma, Inc. by Gilead, Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics, Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Drug Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Products
    • Extension Tube
    • Infusion Bags
    • Intravenous Catheter
    • Pre-Filled Syringe
    • Sterile Insulin Syringe
    • Subretinal Injection Cannula
  • Commercialized Drugs
    • Kymriah
    • Luxturna
    • Provenge
    • Strimvelis
    • Yescarta
    • Zolgensma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of chronic and genetic disorders
5.1.1.2. Growing number of drug approvals for treatment of cellular and genetic disorders
5.1.1.3. Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
5.1.2. Restraints
5.1.2.1. High cost of drug delivery devices
5.1.3. Opportunities
5.1.3.1. Advancements in nanotechnology and development of biomaterials
5.1.3.2. Utilization of AI, ML, and sensor technologies for drug delivery
5.1.4. Challenges
5.1.4.1. Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cell & Gene Therapy Drug Delivery Devices Market, by Products
6.1. Introduction
6.2. Extension Tube
6.3. Infusion Bags
6.4. Intravenous Catheter
6.5. Pre-Filled Syringe
6.6. Sterile Insulin Syringe
6.7. Subretinal Injection Cannula
7. Cell & Gene Therapy Drug Delivery Devices Market, by Commercialized Drugs
7.1. Introduction
7.2. Kymriah
7.3. Luxturna
7.4. Provenge
7.5. Strimvelis
7.6. Yescarta
7.7. Zolgensma
8. Americas Cell & Gene Therapy Drug Delivery Devices Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET RESEARCH PROCESS
FIGURE 2. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET DYNAMICS
TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY EXTENSION TUBE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION BAGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS CATHETER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STERILE INSULIN SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBRETINAL INJECTION CANNULA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY KYMRIAH, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY LUXTURNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PROVENGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STRIMVELIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY YESCARTA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ZOLGENSMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 28. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 29. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 30. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 40. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 41. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 42. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 43. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 44. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 45. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 46. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 47. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 48. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 49. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 50. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 51. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 52. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 53. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 54. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 55. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 56. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 57. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 58. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 59. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 60. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 61. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 66. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 67. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 68. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 69. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 70. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 71. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 72. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 73. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 74. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 75. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 76. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 77. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 78. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 79. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 80. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 81. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 82. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 83. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 84. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 85. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 86. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 87. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 88. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 89. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 90. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 91. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 92. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 93. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 94. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 95. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 96. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 97. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 98. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 99. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 100. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 101. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 102. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 103. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 104. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
TABLE 107. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 108. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cell & Gene Therapy Drug Delivery Devices market, which are profiled in this report, include:
  • Amgen Inc.
  • Bausch & Lomb Incorporated
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co., Ltd.
  • Kite Pharma, Inc. by Gilead
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Pfizer, Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.
  • uniQure N.V.
  • Vericel Corporation

Methodology

Loading
LOADING...

Table Information